The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has launched a new electronic system for registering human medicine export certificates, marking a significant shift from paper-based processes to digital regulatory compliance. The Department of Health and Social Care announcement confirms the system is now operational for pharmaceutical companies seeking to export UK-manufactured medicines.
UK Pharmaceutical Export Process Digitisation
Transition from paper-based to electronic certificate system, 2024
processing
required
availability
Source: MHRA, 2024 | Georgian Medical Journal News
Streamlined Regulatory Compliance
The electronic register represents a modernisation of the UK’s pharmaceutical export oversight system. Companies exporting human medicines from the UK must now use the digital platform to obtain necessary certificates, according to the MHRA guidance.
This digitisation aligns with broader health policy trends toward electronic regulatory systems across Europe. The system aims to reduce processing times and improve traceability of pharmaceutical exports.
Impact on Pharmaceutical Industry
The new system affects all UK-based pharmaceutical manufacturers and distributors seeking to export human medicines to international markets. The MHRA’s digital transformation initiative includes this certificate system as part of broader regulatory modernisation efforts.
Industry stakeholders can now access certificate status updates in real-time, potentially reducing delays in export shipments. The system maintains the same regulatory standards while improving administrative efficiency, according to quality and safety protocols.
The electronic export certificate system processes 100% of human medicine export applications digitally, eliminating paper-based workflows entirely.
— MHRA Digital Systems, Department of Health and Social Care (Government Publication, 2024)
Key takeaways
- All UK human medicine export certificates now processed through electronic system
- Digital platform provides 24/7 access for pharmaceutical companies
- System eliminates paper-based certificate processing entirely
Frequently asked questions
What medicines require electronic export certificates?
All human medicines manufactured in the UK and intended for export to international markets require certificates through the new electronic system. This includes prescription medicines, over-the-counter drugs, and other regulated pharmaceutical products.
How does the digital system improve processing times?
The electronic platform allows real-time application submission and status tracking, replacing postal or email-based paper certificate processes. Companies can access their certificate status 24/7 and receive immediate confirmations when certificates are issued.
Are there any costs associated with the electronic system?
The MHRA maintains the same fee structure for export certificates, with costs determined by medicine type and destination country. The electronic system does not introduce additional fees beyond existing regulatory charges.
The implementation of electronic export certificates reflects the UK’s commitment to regulatory modernisation following Brexit, as the country establishes independent pharmaceutical oversight systems. This digital infrastructure positions the UK to maintain competitive pharmaceutical export capabilities while ensuring robust safety standards for international medicine trade.
Source: Human medicines: register of electronic export certificates
